Childhood obesity is one of the most pressing public health challenges of our time — and its long-term cardiovascular and metabolic consequences make it essential territory for lipidologists and clinicians alike.

In this episode of Lipid Insights, host Peter H. Jones, MD, MNLA sits down with Casey Berman, MD to explore the full picture: how childhood obesity is defined, why its prevalence continues to rise, and the behavioral, societal, and genetic factors fueling the epidemic. They also dive into associated comorbidities and the latest prevention and management strategies — from lifestyle modifications and pharmacotherapy to the evolving role of bariatric and metabolic surgery.

A must-listen for any clinician looking to better support their youngest patients.

Join host Dr. Peter H. Jones for a special episode of Lipid Insights discussing the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Dr. Jones is joined by guideline author and NLA Past President Dr. Joseph Saseen and NLA President-Elect Dr. Dinesh Kalra to break down what clinicians need to know.

From the restoration of LDL-C treatment goals and major conceptual shifts from the 2018 guideline, to primordial and primary prevention, risk assessment, special populations, and real-world implementation challenges, this episode covers it all. The panel also explores the guideline's expanded scope beyond LDL-C to include triglycerides, Lp(a), ApoB, and more.

This is a must-listen episode for anyone involved in dyslipidemia management.

Read the Guidelines here: https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016

In this episode of Lipid Insights, we explore the NLA's recent expert meta-analysis, "Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials."

Lead author Dinesh K. Kalra, MD, MBA and key author Kevin C. Maki, PhD, CLS, MNLA join host Alan S. Brown, MD, MHA, MNLA to examine the relationship between LDL-C reduction and major adverse cardiovascular events in primary prevention trials. Together, they break down the findings, clinical implications, and why early LDL-C lowering remains central to preventing first cardiovascular events.

Read the meta-analysis: https://www.lipidjournal.com/article/S1933-2874(26)00039-5/fulltext